PSA velocity no better than latest PSA value in screening men carrying BRCA1/2 genes

Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …

Over-inflation of the significance of PSA velocity in Kaiser paper

We still haven’t been able to see the full text of the article by Wallner et al. (reported yesterday) suggesting that PSA velocity was as good or better than a single PSA data point in predicting risk for prostate cancer — and for aggressive types of prostate cancer in particular. However, … READ MORE …

PSA velocity and risk for clinically significant prostate cancer

Analysis of data from > 200,000 men, all enrolled in a large California managed care health plan, appears to offer us some “insight into the usefulness of PSA velocity as a detection marker for aggressive prostate cancer.” … READ MORE …

PSA velocity: is it really an appropriate indicator for prostate biopsy — or not?

Last Friday we noted that a new paper by Vickers et al. has formally recommended that PSA velocity be removed from guidelines on the use of diagnostic data to decide whether a man should have a biopsy to assess his potential risk for prostate cancer. We expressed no opinion on the article at that time … READ MORE …

PSA velocity and prostate cancer biopsy guidelines

A new analysis of data from > 5,500 men who participated in the Prostate Cancer Prevention Trial has directly challenged the recommendation in some clinical guidelines regarding the use of PSA velocity as an indicator for immediate biopsy. … READ MORE …

The continuing saga of the value of PSA velocity

An analysis of data from the Rotterdam and Göteborg subsets of men enrolled in the European Randomized Screening for Prostate Cancer (ERSPC) study suggests that PSA velocity is of little value in the identification of men who would benefit from a second biopsy after a first, negative biopsy. … READ MORE …

PSA kinetics do not predict pathology in men on active surveillance

The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data. … READ MORE …